US › Healthcare

Lipocine Inc (LPCN)

US · Healthcare · Biotechnology

$2.13+0.95%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$119,397
Revenue YoY
+27.2%
Net profit
$-3.7M
Profit YoY
-96.9%
EPS
$-0.54
EPS estimate
$-0.48
Net margin
-3,075.4%

EPS came in at -0.54 against a street estimate of -0.48 — a miss of 12.5%.

Key statistics

Market cap
$17.5M
Forward P/E
5.6
P/B
0.77
Book value
$3.05
EPS (TTM)
$-1.96
52-week high
$12.37
52-week low
$1.81
50-day MA
$2.28
200-day MA
$4.59
Beta
0.44

Analyst view

Analysts rate Lipocine Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $6.00.

Shareholding

Insiders
4.51%
Institutions
44.29%

Largest institutional holders

FundStake
Ikarian Capital, LLC6.17%
Squadron Capital Management LLC5.46%
StemPoint Capital LP3.89%
Eversept Partners, LP3.58%
Vanguard Group Inc2.69%
Rosalind Advisors, Inc.2.69%
Vanguard Capital Management, LLC2.43%
AIGH Capital Management, LLC2.43%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Lipocine Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.